Abstract
PURPOSE: The aim of this study was to document the morbidity of urgent subtotal colectomy and ileostomy in patients with severe ulcerative colitis who failed cyclosporin treatment. METHODS: We reviewed the charts of patients with severe ulcerative colitis who did not respond to cyclosporin treatment and underwent urgent subtotal colectomy and Brooke ileostomy at two inflammatory bowel disease centers over the 12-month period ending April 1994. RESULTS: Fourteen patients (6 males; mean age, 34 years) required an urgent subtotal colectomy and Brooke ileostomy after failing treatment with cyclosporin. There were no deaths. Eight patients (57 percent) developed postoperative complications, which included ileus (3), deep vein thrombosis (2), wound infection (2), and partial dehiscence of rectal stump (1). Mean length of postoperative hospital stay was 8.8 days. CONCLUSIONS: These initial data suggest that cyclosporin treatment may not influence the safety of urgent surgical treatment in severe ulcerative colitis.
Similar content being viewed by others
References
Targan SR, Kagnoff MF, Brogan MD, Shanahan F. Immunologic mechanisms in intestinal diseases. Ann Intern Med 1987;106:853–70.
Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16–9.
Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc 1992;67:981–90.
Prokupek DA, Kashyap PK, Targan SR, Plevy SE, Choi PM. Cyclosporin in the treatment of refractory UC: determinants of a successful outcome at 6 months [abstract]. Gastroenterology 1994;106:756.
Lichtiger S, Present DH, Kornbluth A, Michelassi F, Hanauer SB. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–5.
Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986;11:107–32.
Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cyto-toxic T-cell responses by impairing the release of interleukin-1 and interleukin-2. Eur J Immunol 1981;11:657–61.
Elliott JF, Lin Y, Mizel SB,et al. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984;226:1439–41.
Kupiec-Welglinski JW, Filho MA, Strom TB, Tilney NL. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation 1984;38:97–101.
Reed JC, Prystowsky MB, Nowell PC. Regulation of gene expression in lectin-stimulated or lymphokine-stimulated T lymphocytes. Transplantation 1991;4(Suppl):85S-89S.
Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease: effect of cyclosporine. Gut 1990;31:795–9.
Brynskov J, Tvede N, Andersen CB, Vilien M. Increased concentrations of interleukin-1B, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992;33:55–8.
MacDermott RP, Nash GS, Auer IO,et al. Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease. Gastroenterology 1989;96:764–8.
Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology 1987;93:919–24.
Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488–90.
Cockburn I. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune. Transplant Proc 1987;19:1804–7.
Albrechtsen D, Bergan A, Gjone E, Nygaard K, Flatmark A. Elective surgery for ulcerative colitis:colectomy in 158 patients. Scand J Gastroenterol 1981;16:825–31.
Johnson WR, Hughes ES, McDermott FT, Pihl EA, Katrivessis H. The outcome of patients with ulcerative colitis managed by subtotal colectomy. Surg Gynecol Obstet 1986;162:421–5.
Adams DH, Wang LF, Neuberger JM, Elias E. Inhibition of leukocyte chemotaxis by immunosuppressive agents. Transplantation 1990;50:845–50.
Fishel R, Barbul A, Wasserkrug HL, Penberthy LT, Rettura G, Efron G. Cyclosporine A impairs wound healing in rats. J Surg Res 1983;34:572–5.
Vanrenterghem Y, Lerut T, Roels L,et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;1:999–1002.
Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983;36:259–67.
Ritchie JK. Ulcerative colitis treated by ileostomy and excisional surgery. Br J Surg 1972;59:345–51.
Binder SC, Miller HH, Deterling RA Jr. Emergency and urgent operations for ulcerative colitis. Arch Surg 1975;110:284–9.
Albrechtsen D, Bergan A, Nygaard K, Gjone E, Flatmark A. Urgent surgery for ulcerative colitis: early colectomy in 132 patients. World J Surg 1981;5:607–15.
Carter FM, McLeod RS, Cohen Z. Subtotal colectomy for ulcerative colitis: complications related to the rectal remnant. Dis Colon Rectum 1991;34:1005–9.
Kyle SM, Steyn RS, Keenan RA. Management of the rectum following colectomy for acute colitis. Aust N Z J Surg 1992;62:196–9.
Ng RL, Davies AH, Grace RH, Mortensen NJ. Subcutaneous rectal stump closure after emergency subtotal colectomy. Br J Surg 1992;79:701–3.
Penna C, Daude F, Parc R,et al. Previous subtotal colectomy with ileostomy and sigmoidostomy improves the morbidity and early functional results after ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 1993;36:343–8.
Author information
Authors and Affiliations
About this article
Cite this article
Fleshner, P.R., Michelassi, F., Rubin, M. et al. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 38, 1241–1245 (1995). https://doi.org/10.1007/BF02049146
Issue Date:
DOI: https://doi.org/10.1007/BF02049146